Vanessa Broadhurst is Executive Vice President, Global Corporate Affairs, and is a member of the Executive Committee. In this role, Vanessa is responsible for advancing our strategy across Corporate Marketing, Global Communications, Health Equity, and Philanthropic giving. She leads a world-class team who are passionate about changing the trajectory of health for humanity.
Vanessa has more than 25 years of senior leadership experience, having worked for leading global healthcare companies across the U.S. and Europe including Amgen, Novartis, and Abbott.
Prior to her current position, Vanessa served as Company Group Chairman of Global Commercial Strategy for Johnson & Johnson’s Innovative Medicine sector, where she led efforts focused on commercialization and launch strategies that spanned our broad pipeline of products and realized accelerated business growth across six therapeutic areas. During her tenure, Vanessa was a member of the Pharmaceuticals Group Operating Committee, the Research and Development Senior Leadership Team, and responsible for Global Value and Access, Global Commercial Data Sciences, and Global Medical Affairs.
Vanessa joined Johnson & Johnson in 2005 to lead Global Commercial Strategy for Anemia and Oncology Supportive Care. Additionally, she has led several multibillion-dollar U.S. businesses including Cardiovascular and Metabolism, Internal Medicine, and Infectious Disease, where she consistently delivered bottom-line growth and helped grow Johnson & Johnson to become one of the largest and most diversified healthcare companies in the world.
Vanessa sits on the Board of Directors of Zoetis, the largest global animal health company which is committed to nurturing the world and humankind by advancing care for animals. She also is a Board Member of the Ad Council, whose mission is to convene the best storytellers to educate, unite and uplift—by opening hearts, inspiring action and accelerating change. Vanessa is a member of The Executive Leadership Council (ELC), and Executive Sponsor for Johnson & Johnson’s African Ancestry Leadership Council where she is committed to supporting professional talent throughout Johnson & Johnson and within the healthcare industry.
In 2022, SAVOY named Vanessa one of the “Most Influential Black Executives in Corporate America.” She was also recognized as “Healthcare Champion of the Year” by the National Association for Female Executives, and one of the “Top Blacks in Healthcare” by Blackdoctors.org.
Vanessa earned a Master of Business Administration from the Ross School of Business at University of Michigan where she was a Consortium Fellow, and a Bachelor of Arts degree from the University of Colorado, Boulder.
What is Vanessa Broadhurst's net worth?
The estimated net worth of Vanessa Broadhurst is at least $5.68 million as of February 17th, 2026. Broadhurst owns 23,003 shares of Johnson & Johnson stock worth more than $5,679,441 as of February 19th. This net worth evaluation does not reflect any other assets that Broadhurst may own. Learn More about Vanessa Broadhurst's net worth.
How do I contact Vanessa Broadhurst?
Has Vanessa Broadhurst been buying or selling shares of Johnson & Johnson?
Within the last three months, Vanessa Broadhurst has sold $1,508,287.83 of Johnson & Johnson stock. Most recently, Vanessa Broadhurst sold 6,197 shares of the business's stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a transaction totalling $1,508,287.83. Following the completion of the sale, the executive vice president now directly owns 23,003 shares of the company's stock, valued at $5,598,700.17. Learn More on Vanessa Broadhurst's trading history.
Who are Johnson & Johnson's active insiders?
Johnson & Johnson's insider roster includes Vanessa Broadhurst (EVP), Dominic Caruso (VP), Robert Decker (CAO), Joaquin Duato (CEO & Chairman), Peter Fasolo (VP), Alex Gorsky (CEO), William Hait (Insider), Ronald Kapusta (CAO), Ashley McEvoy (EVP), Thibaut Mongon (VP), William Perez (Director), Timothy Schmid (EVP, Worldwide Chairman, MedTech), Michael Sneed (COO), Paulus Stoffels (VP), James Swanson (EVP), Jennifer Taubert (EVP), Mark Weinberger (Director), Kathryn Wengel (EVP), Joseph Wolk (CFO), and Joseph Wolk (Exec. VP & CFO ). Learn More on Johnson & Johnson's active insiders.
Are insiders buying or selling shares of Johnson & Johnson?
During the last year, insiders at the sold shares 4 times. They sold a total of 92,290 shares worth more than $18,237,868.05. The most recent insider tranaction occured on February, 18th when EVP Timothy Schmid sold 22,623 shares worth more than $5,527,477.59. Insiders at Johnson & Johnson own 0.2% of the company.
Learn More about insider trades at Johnson & Johnson. Information on this page was last updated on 2/18/2026.